CPT code 87506 represents a multiplex nucleic acid test that detects six to eleven gastrointestinal pathogens or subtypes responsible for infectious diarrhea, using methods such as multiplex reverse transcription and amplified probe techniques. This testing modality matters nationally because rapid, multiplex molecular diagnostics improve pathogen identification, inform infection control, and guide appropriate clinical management, reducing complications and unnecessary antibiotic use.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how CPT code 87506 is used in clinical practice, typical sites of service, and the clinical context for ordering multiplex gastrointestinal pathogen panels. The publication also summarizes common billing considerations and benchmarks where available, highlights relevant policy updates affecting laboratory molecular diagnostics reimbursement, and outlines implications for coding workflows and laboratory operations.

The content is intended for national audiences including laboratory managers, coding professionals, and policy analysts seeking clarity on clinical purpose, payer coverage context, and operational considerations for use of CPT code 87506 in molecular gastrointestinal pathogen testing.